Skip to main content
. Author manuscript; available in PMC: 2023 Dec 3.
Published in final edited form as: Blood Rev. 2022 Aug 2;57:100996. doi: 10.1016/j.blre.2022.100996

Table 2.

Clinical trials in IDH1mat or IDH2mat AML.

Mutation Study regimen Trial identifier
IDH1mut or IDH2mut  AML
IDH1 mut Ivosidenib or placebo + azacitidine NCT03173248
IDH1 mut Ivosidenib and CPX-351 NCT04493164
IDH1 mut Olutasidenib with azacitidine or cytarabine NCT02719574
IDH2 mut Enasidenib and venetoclax NCT04092179
IDH1mut or IDH2mut Ivosidenib or enasidenib with 7 + 3 followed by cytarabine or mitoxantrone/etoposide consolidation NCT02632708